We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma

Articolo
Data di Pubblicazione:
2018
Citazione:
We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma / Papi, A1; Beghe', Bianca; Fabbri, Lm3; 4,. - In: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. - ISSN 1073-449X. - 197:1(2018), pp. 1-7. [10.1164/rccm.201710-1970ED]
Abstract:
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that anti.IL.5 pathways have been explored for several years for their ability to reduce eosinophilic inflammation and thus to improve the treatment of this disease.
Tipologia CRIS:
Articolo su rivista
Keywords:
Severe asthma, cytokinens, treatment, monoclonal atibodies
Elenco autori:
Autori di Ateneo:
Link alla scheda completa:
https://iris.unimore.it/handle/11380/1147118
Link al Full Text:
Pubblicato in:
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Journal